
Novo Nordisk A/S (NYSE: NVO) recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026. After initially moving higher after the news, NVO stock has drifted lower, likely due to the renewed uncertainty surrounding tariff policy affecting the entire market.
This is the latest move by Novo Nordisk to compete with Eli Lilly and Co. (NYSE: LLY) in the multi-faceted weight loss and obesity market. Earlier this year, Novo announced a partnership with Septerna Inc. (NASDAQ: SEPN) to develop novel drug treatments for obesity and type 2 diabetes.